Condition
Enterocutaneous Fistula
Total Trials
4
Recruiting
1
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (3)
P 1 (1)
Trial Status
Completed2
Unknown1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT04577456Not ApplicableCompleted
Chyme Reinfusion for Type 2 Intestinal Failure
NCT06524401Not ApplicableRecruiting
Novel Post-Surgical Incision Management to Prevent Ostomy Complications
NCT03302598Not ApplicableCompletedPrimary
Assessment of Relation Between Recurrence of Enterocutaneous Fistula and Preoperative C-reactive Protein Level After Complete Surgical Repair
NCT01584713Phase 1UnknownPrimary
Stromal Vascular Fraction (SVF) for Treatment of Enterocutaneous Fistula (HULPUTC)
Showing all 4 trials